As of May 22
| +0.03 / +0.32%|
The 3 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 15.00, with a high estimate of 21.00 and a low estimate of 14.00. The median estimate represents a +58.39% increase from the last price of 9.47.
The current consensus among 5 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since May, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.